News Novartis pulls plug on landmark UK cholesterol trial ORION-17 study has been abandoned, with Novartis opting instead for a smaller global trial.
News Double blow for Sangamo as Novartis, Biogen exit deals The two deals for gene-modifying candidates were worth up to $3.1 billion including milestones.
News AbbVie’s Skyrizi hits the spot in refractory psoriasis Antibody works when IL-17 inhibitors Like Novartis' Cosentyx and Lilly's Taltz fail.
News Sandoz bolsters biosimilars with $400m Slovenia plant New facility will be based at Sandoz' Lek subsidiary, and employ 300 staff when completed.
News FDA removes leash from Verzenio in early breast cancer Drug can now be used as adjuvant therapy without Ki-67 testing, taking a brake off prescribing.
News French court overturns €444m fine for Novartis, Roche Says companies did not abuse a market position to push Lucentis over off-label Avastin in AMD.
News Rezzayo antifungal okayed as Candida auris rings alarm bells Drug is first new echinocandin to be approved for marketing in the US in more than a decade.
R&D Sponsored An inside guide to unlocking clinical research in the UK An inside guide to unlocking clinical research in the UK
